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Abstract: The management of narcolepsy is presently at a turning point. Three main avenues 
are considered in this review: 1) Two tendencies characterize the conventional treatment of 
narcolepsy. Modaﬁ  nil has replaced methylphenidate and amphetamine as the ﬁ  rst-line treat-
ment of excessive daytime sleepiness (EDS) and sleep attacks, based on randomized, double 
blind, placebo-controlled clinical trials of modaﬁ  nil, but on no direct comparison of modaﬁ  nil 
versus traditional stimulants. For cataplexy, sleep paralysis, and hypnagogic hallucinations, 
new antidepressants tend to replace tricyclic antidepressants and selective serotonin reuptake 
inhibitors (SSRIs) in spite of a lack of randomized, double blind, placebo-controlled clinical 
trials of these compounds; 2) The conventional treatment of narcolepsy is now challenged by 
sodium oxybate, the sodium salt of gammahydroxybutyrate, based on a series of randomized, 
double-blind, placebo-controlled clinical trials and a long-term open label study. This treatment 
has a fairly good efﬁ  cacy and is active on all symptoms of narcolepsy. Careful titration up to an 
adequate level is essential both to obtain positive results and avoid adverse effects; 3) A series 
of new treatments are currently being tested, either in animal models or in humans, They include 
novel stimulant and anticataplectic drugs, endocrine therapy, and, more attractively, totally new 
approaches based on the present state of knowledge of the pathophysiology of narcolepsy with 
cataplexy, hypocretine-based therapies, and immunotherapy.
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Introduction
Narcolepsy is a disabling condition characterized by three groups of symptoms: 
excessive daytime sleepiness (EDS) and irresistible sleep episodes, plus or minus 
automatic behaviors; cataplexy, a sudden loss of muscle tone triggered by strong 
emotions such as laughter or humorous experiences, and other abnormal rapid eye 
movement (REM) sleep manifestations, sleep paralysis and hypnagogic hallucinations; 
disturbed nocturnal sleep, and parasomnias. The cardinal symptoms are excessive 
daytime sleepiness/sleep attacks and cataplexy. The diagnosis of narcolepsy rests on 
clinical grounds. However, polysomnography followed by a multiple sleep latency test 
(MSLT) is greatly recommended to document a mean sleep latency 8 min and two 
or more sleep onset REM periods (American Academy of Sleep Medicine 2005).
Recently the second edition of the International Classiﬁ  cation of Sleep Disorders 
(ICSD-2) has recognized three forms of narcolepsy: narcolepsy with cataplexy, 
narcolepsy without cataplexy, and narcolepsy due to medical condition (American 
Academy of Sleep Medicine 2005).
The prevalence of narcolepsy with cataplexy is estimated to be 0.02%–0.05% 
(Hublin et al 1994a; Ohayon et al 2002; Silber et al 2002; Wing et al 2002). Limited 
data suggest that the incidence is 0.74 per 100,000 person-years (Silber et al 2002)). 
Narcolepsy without cataplexy is thought to represent between 10% and 50% of all Neuropsychiatric Disease and Treatment 2008:4(3) 558
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narcolepsy cases, but the precise prevalence is unknown. 
Narcolepsy due to medical condition is exceptional, with 
115 cases published in the world literature (Nishino and 
Kanbayashi 2005).
The age of onset varies from early childhood to 50, with 
a bimodal distribution, including a main peak around the age 
of 15 and a secondary peak around the age of 36 (Dauvilliers 
et al 2001).
The general course of narcolepsy is hard to systematize. 
The pattern tends to be for EDS and irresistible sleep attacks 
to persist throughout life, even if improvements are com-
monly observed after retirement, probably in part due to a 
better schedule of sleep and activity. Cataplexy may vanish 
spontaneously in some patients. Hypnagogic hallucinations 
and sleep paralysis are most often transient. Poor sleep does 
not tend to improve. Narcolepsy has a negative impact on 
several aspects of life such as driving ability, professional 
performance, familial equilibrium, and mood (Broughton 
et al 1981). One particular complication is status cataplecti-
cus characterized by cataplexy lasting hours and days and 
conﬁ  ning the patient to bed. Status cataplecticus occurs either 
spontaneously or, more often, after suspending treatment for 
cataplexy because of adverse effects.
The etiology of narcolepsy is not yet fully clariﬁ  ed. 
However, it is clear that mutations in the hypocretin (orexin) 
receptor 2 gene cause genetic narcolepsy in several animal 
species (Chemelli et al 1999; Lin et al 1999) and there is no 
doubt that hypocretin/orexin deﬁ  ciency is the most frequent 
cause of narcolepsy with cataplexy in humans (Peyron et al 
2000; Thannickal et al 2000).
The management of narcolepsy has evolved over the 
past few years and will likely evolve more dramatically in 
the coming years. Treatment guidelines have been published 
(Standards of Practice Committee of the American Sleep 
Disorders Association 1994; Standards of Practice Commit-
tee 2001; Britton et al 2002; Billiard et al 2006; Keam et al 
2007; Morgenthaler et al 2007).
The treatment of excessive daytime sleepiness and 
sleep attacks, traditionally based on amphetamines and 
amphetamine-like drugs, is now replaced by modaﬁ  nil. 
New antidepressants have replaced tricyclics and selective 
serotonin reuptake inhibitors (SSRIs) in the treatment of 
cataplexy and other abnormal REM sleep manifestations.
Gamma-hydroxybutyrate, a treatment ﬁ  rst used in the 
1980s, has recently re-emerged under the name sodium 
oxybate, as a treatment of all symptoms of narcolepsy.
New approaches including symptomatic neurotransmit-
ters and endocrine therapy, hypocretine-based therapies, 
immune-based therapies, and skin warming or cooling are 
currently being developed.
The conventional treatments 
of narcolepsy
Treatment of excessive daytime 
sleepiness and sleep attacks
Amphetamines
Amphetamines, including d,l-amphetamine, d-amphetamine 
(sulfate) and met-amphetamine (chlorhydrate) have been used 
for narcolepsy since the 1930s (Prinzmetal and Bloomberg 
1935). At low dose, their main effect is to release dopamine – 
and to a lesser extent noradrenaline – through reverse efﬂ  ux 
via monoaminergic transporters, the dopamine transporter 
(DAT) and the norepinephrine transporter (NET). DAT and 
NET move dopamine and norepinephrine, respectively, from 
the outside to the inside of the cell. This process is sodium 
dependent. At higher doses, amphetamine interacts with the 
vascular monoamine transporter 2 (VMAT2). The vesicular-
ization of the monoamines (dopamine, norepinephrine, sero-
tonine, and histamine) in the central nervous system depends 
on VMAT2). At a dose of 10–60 mg/day, amphetamines are 
very effective. However, they may be responsible for a num-
ber of adverse effects, irritability, headache, nervousness, 
palpitations, insomnia, and less often orofacial dyskinesia, 
anorexia, nausea, excessive sweating, and psychosis. Toler-
ance to amphetamine effect may develop in up to one third 
of patients (Mitler et al 1994), addiction is generally not a 
problem in narcoleptic patients (Guilleminault 1993).
Methylphenidate
Methylphenidate, a N-methyl derivative of amphetamine, 
also induces dopamine release, but does not have a major 
effect on monoamine storage. In comparison with amphet-
amines, methylphenidate has a much shorter elimination 
half-life (2–7 hours) (Parkes and Dahlitz 1993). The daily 
dose is 10–60 mg a day. Adverse effects are the same as 
with amphetamines, but milder. Tolerance may develop but 
abuse potential is low. A sustained release form is available 
and can be useful in some cases.
Modaﬁ  nil
Modaﬁ  nil has been available in France for more than 20 years 
under controlled hospital-based prescription. The drug was 
approved in France in 1994 and in the US in late 1998.
Compared with amphetamine, modaﬁ  nil has an addi-
tional phenyl (sulﬁ  nyl group) and an amide instead of an 
amine group, which suggests a distinct mechanism of action. Neuropsychiatric Disease and Treatment 2008:4(3) 559
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However, the mode of action is still unclear even if a 
dopamine reuptake inhibition is very likely involved (Mignot 
et al 1994; Nishino et al 1998; Wisor et al 2001). The elimi-
nation half-life is 13.8 hours and the maximum concentration 
is achieved in 2–4 hours.
Unlike previous drugs modaﬁ  nil has beneﬁ  ted from 
randomized, double-blind, placebo-controlled trials, which 
have shown the drug to be signiﬁ  cantly effective on exces-
sive daytime sleepiness at a dose of 300 mg (Billiard et al 
1994), or at doses of 200 and 400 mg (Broughton et al 1997; 
US Modaﬁ  nil in Narcolepsy Multicenter Group 1998, 2000; 
Beuersterien et al 1999; Moldofsky et al 2000).
The starting dose is 100–200 mg and the usual dose 
between 100 and 400 mg, given either as a single morning 
dose or as a split dose. The most common adverse effects 
are limited. They include headache, nausea, nervousness, 
and rhinitis, especially at the onset of treatment. There is no 
evidence of tolerance (Thorpy et al 2004).
The possibility of induction of human hepatic cytochrome 
P450 enzymes exists, hence an increase of the metabolism 
of oral contraceptives. Accordingly, the usual recommenda-
tion is for the patient to use another form of contraception 
while taking modaﬁ  nil and for one month after stopping the 
medication.
Today modaﬁ  nil is the most widely precribed drug for 
excessive daytime sleepiness. It is effective or very effective 
in 60% of patients and partially effective in 20% (Billiard 
et al 2007). In case of insufﬁ  cient efﬁ  cacy or of fading out 
of the activity, modaﬁ  nil may be supplemented by either 
methylphenidate (regular short-acting formulation) on an 
as-needed basis or at times when sleepiness is most severe, 
or by sodium oxybate (Black and Houghton 2006)
Mazindol
Mazindol is an imidazole derivative with similar pharma-
cological effects to the amphetamines. It is a weak releas-
ing agent for dopamine, but it also blocks dopamine and 
norepinephrine reuptake with high afﬁ  nity. Its elimination 
half-life is around 10 hours. The usual dosage is 2–6 mg/day. 
Mazindol reduces excessive daytime sleepiness in 53%–60% 
of patients (Shindler et al 1985). Adverse effects include 
dry mouth, gastro-intestinal upset, anorexia, headache, and 
sweating. Mazindol has been withdrawn from the market in 
several countries due to reports of valvular abnormalities.
Selegiline
Selegiline is a potent irreversible MAO type-B inhibi-
tor. It is metabolically converted to desmethyl selegiline, 
l-amphetamine and l-methamphetamine. The regular dose 
is 10–40 mg/day. It has been shown to signiﬁ  cantly reduce 
excessive daytime sleepiness at a dose of at least 20 mg 
(Mayer et al 1995). The main adverse effects are sympa-
thomimetic and interaction with other drugs (Hublin et al 
1994b; Mayer et al 1995). A diet low in tyramine is recom-
mended with higher dosages of selegiline to avoid the risk 
of hypertensive reactions.
Pemoline
Pemoline is an oxazolidine derivative with a long half-life 
(12 hours), which selectively blocks dopamine reuptake and 
only weakly stimulates dopamine release. This drug is usu-
ally better tolerated than amphetamine in terms of adverse 
effects (Mitler et al 1986). However, due to its potential fatal 
hepato-toxicity, it has been withdrawn from the market in 
most countries.
Behavioral treatment
In addition to pharmacological treatment, behavioral treat-
ment measures are always advisable. Essentially, the studies 
available (Rogers et al 2001; Broughton et al 2007) support 
the recommendation to take planned naps during the day, 
as naps decrease sleep tendency and shorten reaction time. 
Because of limitations on work or home times, naps are best 
scheduled on a patient-by-patient basis.
Treatment of cataplexy and other REM 
sleep manifestations, sleep paralysis, 
and hypnagogic hallucinations
Tricyclic antidepressants
Cataplexy was primarily treated using a tricyclic antidepres-
sant, imipramine (Akimoto et al 1960). Tricyclic antidepres-
sants are monoamine reuptake inhibitors but lack speciﬁ  city 
for any single monoamine, both with respect to their parent 
compounds and because of the existence of active metabolites 
(Tatsumi et al 1997). Possible mechanisms of action include 
anticholinergic effects, serotonergic reuptake inhibition, or 
adrenergic reuptake inhibition. Tricyclic antidepressants 
are active on cataplexy at doses below usual antidepressant 
dose range efﬁ  cacy. Clomipramine (in Europe and Japan) 
and protriptyline (in the US) have been the most widely 
used. Clomipramine is principally a serotonergic reuptake 
inhibitor, but metabolizes into desmethylimipramine, a 
metabolite with adrenergic effects. Active doses are typically 
25–75 mg daily. However, low doses of 10–20 mg daily are 
often effective, and it is always advisable to start with them 
to avoid anticholinergic effects. Protriptyline is mostly a Neuropsychiatric Disease and Treatment 2008:4(3) 560
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norepinephrine uptake inhibitor. Active doses are 2.5–10 mg 
daily. As for clomipramine, it is always advisable to start 
with low doses.
Adverse effects consist of anticholinergic effects includ-
ing dry mouth, sweating, constipation, tachycardia, weight 
gain, hypotension, difﬁ  culty in urinating, and impotence. In 
the case of abrupt withdrawal, a marked increase in number 
and severity of cataplectic attacks, a situation referred to as 
rebound cataplexy, or even status cataplecticus may occur 
(Martinez-Rodriguez et al 2002).
Monoamine oxidase (MAO) type-A inhibitors
MAO type-A inhibitors increase the activity of endogenous 
catecholamines by inhibiting monoamine oxidase. Although 
these drugs, specially phenelzine, have been used with suc-
cess in small series (Wyatt et al 1971), they lack controlled 
clinical trials. Moreover these drugs have adverse effects 
including orthostatic hypotension, edema, weight gain, and 
impotence. Above all the ingestion of tyramine-rich foods, 
such as cheese and wine, may result in hypertensive crisis. 
Thus these drugs are not in use any more.
Selective serotonin-reuptake inhibitors (SSRIs)
These compounds are much more selective than tricyclic 
antidepressants toward the serotonergic transporter, although 
most of them have afﬁ  nities for other monoamine transporters 
at 10–100 times higher concentrations (Schachter et al 1980; 
Langdon et al 1986). In comparison with tricyclics, higher 
doses are required and effects less pronounced (Nishino and 
Mignot 1997). The daily dosage varies with the product. As 
a group, SSRIs possess the following adverse effects: head-
ache, nausea, weight gain, dry mouth, erectile and ejaculation 
dysfunction, and decreasef libido. Adverse effects are less 
pronounced than with tricyclic antidepressants. However, a 
ﬂ  attened affect or sexual difﬁ  culty may be encountered.
Newer antidepressants
Despite the lack of randomized, double-blind, placebo con-
trolled studies, some products are increasingly used.
Noradrenergic uptake inhibitors
Viloxazine at a dose of 100–300 mg per day (Guilleminault 
et al 1986), reboxetine at a dose of 2–10 mg (Larrosa et al 
2001) and atomoxetine at a dose of 40–60 mg per day 
(Niederhofer 2005) are generally active against cataplexy. 
Note that the ﬁ  rst two compounds are available only in a 
few European countries. Adverse effects are limited with 
the exception of rash, nausea with viloxazine, minimal 
sedation, and cardiovascular liabilities with reboxetine, and 
tachycardia, hypotension, and the rare but potential liver 
toxicity with atomoxetine
Noradrenaline and serotonin-reuptake inhibitors
Venlafaxine is increasingly used at a dose of 37.5–300 mg 
daily. The main adverse effects are gastrointestinal upset 
and less frequently asthma and hypertension (Smith et al 
1996). Status cataplecticus has been reported with a shift 
from immediate release venlafaxine to the extended release 
formulation (Plazzi et al 2007).
Mazindol and selegiline
Each of these drugs has combined anticataplectic effects 
and stimulant properties (Shindler et al 1985; Iijima et al 
1986; Roselaar et al 1987). No comparative study with other 
anticataplectic drugs is available.
Behavioral treatment
In contrast with excessive daytime sleepiness, there is no 
established behavioral treatment of cataplexy, except for 
avoiding situations that trigger cataplexy.
Treatment of disturbed nocturnal sleep
The standard treatment is based on hypnotics, benzodiaz-
epines and non-benzodiazepines, which may delay the ﬁ  rst 
awakening of the night. However, a single study (Thorpy 
et al 1992) has shown an improvement of sleep efﬁ  ciency 
and overall sleep quality with triazolam 0.25 mg given for 
two nights only, and no study has been performed with 
either zopiclone (now referred to as ezopiclone in the US) 
or zolpidem or zaleplon.
Sodium oxybate, a new approach 
to the treatment of narcolepsy
Gamma-hydroxybutyrate (GHB) is a natural metabolite of 
gamma-aminobutyrate that may act as a neurotransmitter 
via its own receptors and via the stimulation of GABA-B 
receptors (Maitre 1997; Pardi and Black 2006).
Broughton and Mamelak (1979) were the ﬁ  rst to support 
that GHB was useful to control cataplexy, enhance daytime 
alertness and improve night sleep in narcoleptic patients, and 
for years GHB was used at a dose of 2.5 g at bedtime and 
1.25 g later in the night, with inconstant results. Moreover, 
due to its misuse in athletes for its metabolic effects and its 
use as a date rape because of its rapid sedative effects, the 
use of GHB became extremely restricted.
However, based on the early clinical results, GHB has 
re-emerged in the past few years under the name sodium Neuropsychiatric Disease and Treatment 2008:4(3) 561
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oxybate, the sodium salt of GHB, which is used for the 
exogenous administration of GHB. Sodium oxybate has been 
tested in a number of randomized, double blind, placebo–
controlled trials. Main results have been a dose-dependent 
(3 or 4.5–9 g nightly) reduction of EDS and sleep attacks, 
signiﬁ  cant at the 6 or 9 g doses (US Xyrem® Multicenter 
Study Group 2002; Xyrem® International Study Group 
2005); a dose-dependent (3 or 4.5–9 g nightly) reduction of 
the number of cataplectic attacks signiﬁ  cant at the 9 g dose 
(US Xyrem® Multicenter Study Group 2002, 2004; Xyrem® 
International Study group 2005); and a reduction of night-
time awakenings at the 6 g dose, becoming signiﬁ  cant at 
the 9 g dose (US Xyrem® Multicenter Study Group 2002). 
Moreover a long-term (12 months) open label study showed 
diminished EDS, signiﬁ  cant at 4 weeks, maximal after 8 
weeks; a signiﬁ  cant diminution of cataplectic attacks; and 
night-time awakenings less frequent, although not signicantly 
(US Xyrem® Multicenter Study Group 2003). Finally a recent 
randomized, double blind, placebo-controlled trial showed 
that modaﬁ  nil and sodium oxybate were both effective on 
EDS, with an additive effect (Black and Houghton 2006).
Sodium oxybate is given at a starting dose of 4.5 g/night 
divided into two equal doses of 2.25 g/night. The dose may 
be increased to a maximum dosage of 9 g/night, divided 
into two equal doses of 4.5 g/night, by increments of 1.5 g 
at 2-week intervals. Most patients will start to feel better 
within the ﬁ  rst few days, but optimal response at any given 
dose may take as long as 8–12 weeks.
The most problematic adverse effect was expected to be 
drug abuse. However, the monitored prescription program 
in the US revealed that this is a very low risk in narco-
leptic patients. In the various clinical trials of the product 
(US Xyrem® Multicenter Study Group 2002; Xyrem® 
International Study Group 2005) adverse events with 5% 
incidence included nausea, vomiting, dizziness, and enuresis. 
Today, with the clinical experience accumulated over the 
world, nausea appears as the main adverse effect, although 
it can be treated effectively with anti-emetic drugs. Enuresis 
is relatively rare. On the other hand psychiatric effects such 
as depression or suicidal ideation are to be considered and 
it is advisable not to prescribe sodium oxybate to depressed 
hypersomniac patients
Recommendations (Table 1)
Excessive daytime sleepiness 
and sleep attacks
A conservative therapy, based on the well tested efﬁ  cay of 
the drug and its limited adverse effects, consists of using 
modaﬁ  nil, in a split dose strategy, either with 200 mg at 7:00 
and 12:00 or 400 mg in the morning and 200 mg at noon 
(Schwartz et al 2004), as the ﬁ  rst-line treatment. In case of 
insufﬁ  cient efﬁ  cacy or of secondary relapse, modaﬁ  nil is 
supplemented with either methylphenidate (on an as-needed 
basis) or sodium oxybate at a dose of 4.5 g in two divided 
doses at night. Finally severe and intractable excessive day-
time sleepiness may require the use of amphetamine.
A more recent therapeutic attitude consists in using 
sodium oxybate as a ﬁ  rst line treatment based on an aver-
age better response of patients to sodium-oxybate and on 
some results of Black and Houghton’s study (2006) (sig-
niﬁ  cant reduction of ESS scores at the end of the trial in 
the sodium-oxybate and in the sodium-oxybate/modaﬁ  nil 
groups, not in the modaﬁ  nil group, and fewer weekly sleep 
attacks at the end of the trial in the sodium oxybate and in 
the sodium oxybate/modaﬁ  nil groups, not in the modaﬁ  nil 
group). Supplementation with modaﬁ  nil is indicated in case 
of insufﬁ  cient efﬁ  cacy (Black and Houghton 2006). Having 
to take a second dose during the night is not a problem for a 
large majority of patients and some content themselves with 
Table 1 Recommendations for the treatment of narcolepsy. A. Excessive 
daytime sleepiness/sleep attacks. B. Cataplexy, sleep paralysis, and hypnagogic 
hallucinations. C. Disturbed nocturnal sleep
A
• Conservative  therapy  • More  recent  therapy
 Modaﬁ  nil 100–400 mg/day    Sodium oxybate at a starting dose of
  in a split dose,    4.5 g/night, divided into 2 equal
  possibly supplemented with     doses of 2.25 g, incremented by 1.5 g
  either     at a 2-week interval, up to a
  methylphenidate or sodium     maximum of 9 g, possibly 
  oxybate    supplemented with modaﬁ  nil
  Dexamphetamine in case of
  severe and Intractable EDS
B
• Conservative  therapy  • More  recent  therapy
 –  ﬁ  rst line    Sodium oxybate at a starting dose
  Venlafaxine 37.5–300    of 4.5 equal doses of 2.25 g,
  mg/day or    incremented by 1.5 g at a 2-week
  Atomoxetine 40–60    interval, up to a maximum of 9 g
 mg/day   
  – second line
 Clomipramine  10–60
  mg/day or SSRI
C
• Conservative  therapy  • More  recent  therapy
  Benzodiazepine or    Sodium oxybate at a
  nonbenzodiazepine    starting dose of 4.5 g/night divided
  hypnotic: one tablet at    into 2 equal doses of 2.25 g, 
  bedtime    incremented by 1.5 g at a 2-week
      interval, up to a maximum of 9 gNeuropsychiatric Disease and Treatment 2008:4(3) 562
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one dose when they do not wake up during the night. Patients 
must refrain from alcohol; if they have absorbed alcohol at 
dinner they should not take the ﬁ  rst dose of the night.
In either case the place for other stimulants, seligiline or 
mazindol, has become extremely limited
Cataplexy and other REM sleep 
manifestations
The conservative attitude is to use new antidepressants, 
specially venlafaxine or atomoxetine, based on their rec-
ognized efﬁ  cacy and the absence of major adverse effects, 
in spite of their lack of randomized, double-blind, placebo 
controlled clinical trials, while the more recent therapeutic 
approach, based on multiple randomized, double-blind, 
placebo-controlled clinical trials, is to use directly sodium 
oxybate and titrate the dose up to an adequate level, to 
obtain positive results and avoid adverse effects, as indi-
cated for the treatment of excessive daytime sleepiness and 
sleep attacks.
Should these treatments be inefﬁ  cient tricyclic antidepres-
sants or SSRIs can be tried.
Disturbed nocturnal sleep
The conservative approach is to use benzodiazepines or non 
benzodiazepines. However, the best current treatment is 
sodium oxybate in two nightly doses.
Approval by agencies (Table 2)
Reﬂ  ecting the limited number of medications which have 
been tested through randomized, double blind, placebo 
controlled, clinical trials, only a few medications, mainly 
modaﬁ  nil, methyphenidate and sodium oxybate have been 
approved by the ofﬁ  cial agencies, European Medicines 
Agency (EMEA), US Food and Drug Administration (US 
FDA), and national agencies .
Special issues
Associated conditions
Obstructive sleep apnea syndrome (OSAS) (Chokroverty 
1986; Kales et al 1987; Mayer et al 2002), periodic limb 
movements in sleep (PLMS) (Montplaisir et al 2000; Mayer 
et al 2002), and depression (Merrit et al 1992; Mayer et al 
2002) are more prevalent in narcoleptic patients than in the 
general population. OSAS aggravates EDS. It should be 
treated no differently to the general population. There is no 
documented effect of PLMS on excessive daytime sleepines 
in narcoleptic patients and there is usually no indication 
to treat them. As for depression, antidepressant drugs and 
psychotherapy are indicated. However, there is no systematic 
study of these treatments in narcoleptic patients.
REM sleep behavior disorder (RBD)
There is a high incidence of RBD in narcoleptic patients 
(Schenck and Mahowald 1992; Nightingale et al 2005; 
Marelli et al 2006). Tricyclic antidepressants and the SSRIs 
may trigger or exacerbate RBD. Despite the lack of a speciﬁ  c 
therapeutic trial in narcoleptic patients, clonazepam is recom-
mended. According to Boeve et al (2003), melatonin at a dose 
of 3–13 mg/night would be successful in 57% of cases.
Child narcolepsy
There is no consistent, randomized, placebo-controlled, 
clinical trial available in narcoleptic patients younger 
than 18 years. However, children deserve to be treated 
as well, and it is even vital to treat the condition as early 
as possible, in order to avoid the occurrence of school 
difﬁ  culties. Thus the same drugs as for adults are used, 
Table 2 Approval of the various medications by European and US 
agencies.  A. Medications for EDS and sleep attacks (B, Belgium, DK, 
Denmark, F, France, D, Germany, CH, Switzerland). B. Medications 
for cataplexy (I, Italy, SP, Spain, S, Sweden, CH Switzerland, UK, 
United Kingdom, B, Belgium, DK, Denmark, F, France, D, Germany) 
(RIs, reuptake inhibitors). C. Medications for disturbed nocturnal 
sleep of narcolepsy with cataplexy patients
A
Medications EMEA  US  FDA
Modaﬁ  nil  approved  approved
Sodium oxybate  approved  approved
Methylphenidate  approved in B, DK, F, D, CH  approved
Dexamphetamine not  approved  approved
Methamphetmine not  approved  not  approved
Mazindol not  approved  not  approved
Selegiline not  approved  not  approved
B
Medications EMEA  US  FDA
Sodium oxybate  approved  approved
Clomipramine  approved in I, SP, S, CH, UK  not approved
Protriptyline not  approved  not  approved
SSRIs  approved in B, DK, F, D, CH  not approved
Noradrenaline RIs  not approved  not approved
Nor./serotonin RIs  not approved  not approved
Mazindol not  approved  not  approved
Selegiline not  approved  not  approved
C
Medications EMEA  US  FDA
Benzodiazepines or   not approved  not approved
nonbenzodiazepines
Sodium oxybate  not approved  not approvedNeuropsychiatric Disease and Treatment 2008:4(3) 563
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on the condition of initially prescribing at the weakest 
possible dose. Interestingly, two off-label studies have 
been conducted in children. A ﬁ  rst study has assessed 
the effects of modaﬁ  nil on excessive daytime sleepi-
ness, mood, and academic performance in 13 children 
with narcolepsy or idiopathic hypersomnia. Subjective 
(as reported by parents) and objective assessments were 
performed. For approximately 90% of the children tested, 
parents reported a favorable response with the reduction in 
sudden sleep attacks. Seven children underwent repeated 
nocturnal polysomnography and multiple sleep latency 
test (MSLT), a test measuring sleep latency ﬁ  ve times 
a day to evaluate the degree of sleepiness, and the mean 
sleep latency was signiﬁ  cantly prolonged (Ivanenko et al 
2003). In a second study assessing the effects of sodium 
oxybate in 8 children with narcolepsy with cataplexy, 7/8 
improved. Cataplexy frequency decreased and the score on 
the Epworth Sleepiness Scale, a behavioral assessment of 
sleepiness, improved (Murali et al 2006).
Pregnancy
In general, due to insufﬁ  cient clinical studies, stimulant 
and anti-cataplectic drugs are not recommended during 
pregnancy. Thus, it is advisable to progressively withdraw 
pregnant women from their medication(s). The withdrawal 
must be slow to avoid a marked cataplexy rebound that usu-
ally occurs on day 3 or 4.
Status cataplecticus
Abrupt withdrawal of those antidepressants which decrease 
REM sleep, specially tricyclic antidepressants and SSRIs, 
may induce a signiﬁ  cant rebound of cataplexy, or even a 
status cataplecticus. This symptom is generally difﬁ  cult to 
treat, thus the need for slow discontinuation of the antidepres-
sant when required. The recommended withdrawal schedule 
is one dose every 4 days.
Good practice points
Once diagnosed, patients must be given as much informa-
tion as possible about their condition (nature of the disorder, 
genetic implication, medications available) and their potential 
adverse effects to help them cope with a potentially debili-
tating condition.
Regular follow-up is essential to monitor response to 
treatment, adapt the treatment in case of insufﬁ  cient response 
to treatment or adverse effects, and above all encourage 
the patient to stand on therapy, as stimulants provide, at 
best, moderate improvement in alertness rather than full 
restoration. Another polysomnographic evaluation of patients 
should be considered in case of worsening of symptoms.
Future treatments
Current treatments for human narcolepsy are symptom-
atically based. However, given the major developments in 
understanding the neurobiological basis of the condition, new 
therapies are likely to emerge. There are currently several 
focuses for future treatment
Symptomatic neurotransmitters
Novel compounds in development include stimulants and 
anti-cataplectic drugs.
1. Armodafinil is the r-enantiomer of the racemic 
compound, modaﬁ  nil. Modaﬁ  nil contains equal amounts 
of both the r-enantiomer and the s-enantiomer. The 
r-enantiomer has a half-life of 10–14 hours versus 3–4 
hours for the s-enantiomer. In addition, elimination of 
the s-enantiomer is three times faster than elimination of 
the r-enantiomer. In association with the longer half-life 
of armodaﬁ  nil, plasma concentrations in humans have 
been found to be higher during wakefulness later in the 
day when compared with racemic modaﬁ  nil. Armodaﬁ  nil 
was evaluated through a multicenter, randomized, double-
blind, placebo-controlled trial including 196 patients with 
narcolepsy (Harsh et al 2006). Armodaﬁ  nil signiﬁ  cantly 
improved ability to sustain wakefulness throughout the day 
in patients with narcolepsy. It also signiﬁ  cantly improved 
overall clinical condition, memory, attention, and fatigue 
compared with placebo.
2. For antidepressant therapies novel dual (duloxetine, 
milnacipram) (Kent 2000) and triple (dopamine, serotonin, 
and adrenergic, eg, DOV 216,303) (Beer et al 2004) mono-
aminergic reuptake inhibitors are being tested.
3. The importance of histamine in sleep regulation 
has long been suspected considering the sedative effects 
of the H1 receptor antagonist. Thus the use of H1 recep-
tor antagonists was a logical possibility of treatment. 
Unfortunately there is a lack of available CNS-penetrating 
compounds. However, it was shown, as early as 1990, 
that oral administration of alpha-methylhistamine, a H3 
receptor agonist, signiﬁ  cantly increased deep slow wave 
sleep, while that of thiopiramide, a H3 receptor antagonist, 
enhanced wakefulness in a marked and dose-dependent 
manner (Lin et al 1990). According to the same author (Lin 
2000) H3-receptor antagonists, through desinhibition of 
H3-autoreceptors, would enhance synaptic histamine that in 
turn would activate post-synaptic H1-receptors, promoting Neuropsychiatric Disease and Treatment 2008:4(3) 564
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wakefulness. In this context it is of special importance that 
H3-receptor antagonists and H3-receptor inverse agonists 
have been shown to be effective on sleepiness and cataplexy 
in narcoleptic canines (Tedford et al 1999) and that thiopi-
ramide, a H3-receptor antagonist, signiﬁ  cantly enhanced 
wakefulness in orexin/ataxin-3 narcoleptic mice (Shiba 
et al 2004). Next step will be the trial of H3-receptors in 
human narcoleptics.
Endocrine therapy
Thyrotrophin-releasing hormone (TRH) (Nishino et al 1997) 
and TRH agonists (Riehl et al 2000) have alerting properties. 
Moreover TRH has been shown to increase wakefulness and 
decrease cataplexy in canine narcolepsy (Nishino et al 1997). 
Whether these promising results in animal models will also 
extend to humans remains to be established.
Hypocretin-based therapies
There is no doubt that hypocretin/orexin deﬁ  ciency is the 
cause of most narcolepsy in humans (Peyron et al 2000; 
Thannickal et al 2000). Thus the best standard for narcolepsy 
treatment is likely to aim at replacing the missing neurotrans-
mitter. Various approaches may be considered:
1. Administration of hypocretin-1 (more stable than 
hypocretin-2) in both the blood and CSF. However, the 
blood–brain barrier is quite impermeable to hypocretin-1. 
Intranasal administration holds promise as hypocretin can 
get into the brain when administered through the nasal route 
(Hanson et al 2004). Experiments in humans are needed.
2. Cell transplantation. It was recently demonstrated 
that hypocretin neurons suspension cells, derived from 
posterior hypothalamus of 8- to 10-day-old rat pups, can 
survive when transplanted into the pons (a region of the 
brain that is innervated by hypocretin axons but where the 
hypocretin somata are not present) in adult rats (Arias-
Carrion et al 2004, 2006). These studies highlight the 
potential use of transplants as a therapeutic tool in order to 
treat narcolepsy. However, there are several issues at stake: 
low survival rate of transplanted cells, limited availability 
of donor cells, and immune reaction to the graft in view of 
the autoimmune hypothesis of narcolepsy. One possibility 
could be genetic engineering of cells delivering hypocretins, 
either using stem cell technology or genetically modiﬁ  ed 
transplanted cells.
3. Gene therapy. Viral delivery of a transgene allowing 
the expression of hypocretin without proper anatomical 
distribution has been shown to be effective in mice (Miedaa 
et al 2004). However, an appropriate vector is needed.
Immunotherapy
Narcolepsy is a presumed autoimmune disorder (Silber et al 
2007) and attempts to modify the immune process have 
been undertaken. Intil now steroids have been ineffective 
(Hecht et al 2003), while intravenous immunoglobulins 
(Lecendreux et al 2003; Dauvilliers et al 2004; Zuberi et al 
2004; Fronczek et al 2008) as well as plasmaphoresis (Chen 
et al 2005) have given equivocal results.
Manipulation of skin temperature 
and nocturnal sleep
Skin-temperature regulation is altered in narcolepsy patients 
(Fronczek et al 2006). Interestingly proximal skin warning 
and distal skin cooling have been shown to lead to an increase 
in slow wave sleep and REM sleep and a decrease of wake-
fulness (Fronczek et al 2007), raising the possibility that 
temperature manipulation could supplement other established 
methods to improve nocturnal sleep in narcolepsy patients.
Conclusion
The current therapies of narcolepsy with cataplexy have been 
reviewed, as well as the present state of research on future 
therapeutic approaches.
On the former, several issues deserve consideration. 
Noradrenaline reuptake inhibitors and noradrenaline and 
serotonin reuptake inhibitors are extensively used in the 
treatment of cataplexy, but they totally lack randomized, 
double-blind, placebo-controlled studies for this indication, 
and their approval by major pharmacological agencies is 
not on the program. Due to its efﬁ  cacy on the three groups 
of symptoms of narcolepsy, sodium oxybate is a fascinating 
alternative to the conventional treatment of narcolepsy with 
cataplexy. However, its position versus modaﬁ  nil and new 
antidepressants is not yet settled.
As for future therapeutic approaches, the most challeng-
ing ones are hypocretin–based therapies. However, it is still 
too early to predict which of them will be available in the 
coming years.
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